A new Mount Sinai program takes a holistic, multidisciplinary approach to managing obstructive sleep apnea (OSA) among patients with obesity. It is a timely undertaking, not only because the prevalence of obesity is rising in the United States, but also because of the recent FDA approval of tirzepatide (Zepbound®) as a treatment for moderate to severe OSA among adults with obesity.